Avoid concomitant use with strong CYP3A inhibitors. If concomitant use is unavoidable, reduce the dose of capmatinib and monitor the patient for adverse reactions.
When used concomitantly with moderate CYP3A inhibitors, reduce the dose of capmatinib and monitor the patient for adverse reactions.
Avoid concomitant use of capmatinib with strong or moderate CYP3A inducers.
from FDA,2024.09
As a novel AKT inhibitor, the drug interactions of capivasertib represent a crit···【more】
Release date:2026-01-13Recommended:29
Although capivasertib offers a new treatment option for specific cancers, its ef···【more】
Release date:2026-01-13Recommended:28